{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:04:16Z","timestamp":1789038256797,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,21]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Treosulfan, a low-toxicity alkylating agent, can be used effectively as part of conditioning for HSCT in children with CGD. Long-term follow-up is required to ascertain effects, particularly on gonadal function and compare with other regimens.<\/jats:p>","DOI":"10.1182\/blood-2016-03-704015","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T23:55:04Z","timestamp":1464047704000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":119,"title":["Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience"],"prefix":"10.1182","volume":"128","author":[{"given":"Beatriz","family":"Morillo-Gutierrez","sequence":"first","affiliation":[{"name":"Department of Paediatric Immunology, Great North Children\u00b4s Hospital, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Beier","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Rao","sequence":"additional","affiliation":[{"name":"Paediatric Bone Marrow Transplant, Great Ormond Street Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Burroughs","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"The University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Center Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Ewins","sequence":"additional","affiliation":[{"name":"Paediatric Bone Marrow Transplantation Schiehallion Unit, Royal Hospital for Sick Children, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[{"name":"Paediatric Bone Marrow Transplantation Schiehallion Unit, Royal Hospital for Sick Children, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, Prague, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Krol","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, Prague, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[{"name":"Pediatric Haematology\/Oncology, University Medical Centre, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Zaidman","sequence":"additional","affiliation":[{"name":"Rambam Hospital, Haifa, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University, Wroclaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An","family":"Talano","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Woolfrey","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"The University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[{"name":"Lady Cilento Children\u2019s Hospital, Brisbane, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[{"name":"University of Medical Sciences, Poznan, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Veys","sequence":"additional","affiliation":[{"name":"Paediatric Bone Marrow Transplant, Great Ormond Street Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Walter","family":"Sykora","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Gennery","sequence":"additional","affiliation":[{"name":"Department of Paediatric Immunology, Great North Children\u00b4s Hospital, Newcastle Upon Tyne, United Kingdom;"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slatter","sequence":"additional","affiliation":[{"name":"Department of Paediatric Immunology, Great North Children\u00b4s Hospital, Newcastle Upon Tyne, United Kingdom;"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"Suppl 1","key":"2019111903255333000_B1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jinf.2014.07.013","article-title":"Recent advances in chronic granulomatous disease.","volume":"69","author":"Goldblatt","year":"2014","journal-title":"J Infect"},{"issue":"8","key":"2019111903255333000_B2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/cid\/ciu1154","article-title":"Common severe infections in chronic granulomatous disease.","volume":"60","author":"Marciano","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2019111903255333000_B3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry.","volume":"152","author":"Jones","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2019111903255333000_B4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","article-title":"Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation.","volume":"132","author":"Cole","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2019111903255333000_B5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1183\/09031936.00118414","article-title":"Pulmonary manifestations in adult patients with chronic granulomatous disease.","volume":"45","author":"Salvator","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"2019111903255333000_B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2141.2009.07614.x","article-title":"Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.","volume":"145","author":"Soncini","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111903255333000_B7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.iac.2010.01.003","article-title":"Hematopoietic stem cell transplantation for chronic granulomatous disease.","volume":"30","author":"Seger","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"2019111903255333000_B8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10875-012-9758-0","article-title":"Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant.","volume":"33","author":"Cole","year":"2013","journal-title":"J Clin Immunol"},{"issue":"13","key":"2019111903255333000_B9","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood-2002-02-0583","article-title":"Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.","volume":"100","author":"Seger","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111903255333000_B10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1056\/NEJM200103223441203","article-title":"Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.","volume":"344","author":"Horwitz","year":"2001","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"2019111903255333000_B11","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bbmt.2010.09.008","article-title":"Chronic granulomatous disease: lessons from a rare disorder.","volume":"17","author":"Segal","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111903255333000_B12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/eci.12.9","article-title":"Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.","volume":"8","author":"Chiesa","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"9915","key":"2019111903255333000_B13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"2019111903255333000_B14","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2019111903255333000_B15","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111903255333000_B16","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111903255333000_B17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","article-title":"Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.","volume":"94","author":"Boztug","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111903255333000_B18","doi-asserted-by":"crossref","first-page":"e61637","DOI":"10.1371\/journal.pone.0061637","article-title":"Improved clinical outcomes of high risk \u03b2 thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.","volume":"8","author":"Mathews","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2019111903255333000_B19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.","volume":"19","author":"ten Brink","year":"2014","journal-title":"Drug Discov Today"},{"issue":"2","key":"2019111903255333000_B20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.beha.2008.02.008","article-title":"Diagnosis and manifestations of chronic graft-versus-host disease.","volume":"21","author":"Filipovich","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2019111903255333000_B21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12185-009-0433-z","article-title":"Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC.","volume":"90","author":"Klaudel-Dreszler","year":"2009","journal-title":"Int J Hematol"},{"issue":"2","key":"2019111903255333000_B22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/pbc.25225","article-title":"Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.","volume":"62","author":"Oshrine","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111903255333000_B23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903255333000_B24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen.","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111903255333000_B25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bjh.13497","article-title":"Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan.","volume":"170","author":"Panasiuk","year":"2015","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1182\/blood-2016-10-745455","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/3\/440\/1358815\/440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/3\/440\/1358815\/440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:26:09Z","timestamp":1574133969000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/3\/440\/35541\/Treosulfanbased-conditioning-for-allogeneic-HSCT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,21]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-704015","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood-2016-10-745455","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,21]]}}}